Frontage Laboratories - CRO - Labs in USA and China - July 2011

1. Full Service US Based global CRO (973) 934-1171

4. Systemic exposure

5. Absorbance

6. Clearance

7. Distribution

9. In vivovalidation

11. Preclinical / DMPK Services

12. Dosage Formulation Development

13. CTM Manufacturing

14. Clinical Study Execution in US and China

15. Bioanalysis & Biomarker / Immunology

16. Regulatory filing, GMP Consulting and SupportCommercial Launch Drug Development Candidate (ADMET) Target Discovery & Validation HTS Screening Lead Optimization Registration Phase I Hits to Leads Phase II Phase III

17. FRONTAGE Milestones Expanded Analytical Services & CTM Mfg moved to Exton, PA Launched Clinical Service Center in Beijing Acquired ABR CRO Expanded Operations in Malvern, PA (Bioanalytical, Analytical, PRD and API/Organic Synthesis) Initiated Operations in NJ Investment – Clinical Services with ABR (CRO-1994) Launch of Beijing CMC Center 2002 1 employee 2004 2006 2007 2008 2009 2011 ~250 employees 2010 Launched DMPKOperations AAALAC Certification 2009 Launched Zhengzhou Clinical Center Launched Shanghai Facility (Bioanalytical, Analytical Services)

19. Regulatory Affairs

21. Biomarkers

22. DMPK

24. DMPK / Biomarkers

26. 80-beds The First Teaching Hospital of Jilin University

27. 80- beds at Henan TCM University Hospital - Q3 11

29. Late phase clinical studies

30. Data management/support4

33. Reference Standard Synthesis

34. Metabolite ID and Synthesis

35. Impurity Identification and Purification Projects

36. Process Development & Optimization

38. Sterile Dosage Forms

39. Topical Dosage Forms

41. >200 Method Development/Validation since 2008

43. Immediate and Controlled Release Development Expertise

45. Facilities in US and China

46. Full-time Principle Investigator with Emergency Medicine background

47. BLS and ACLS trained staff

49. Absolute and Relative BA, fed /fasted BE, food effect, PK/PD studies

50. Drug / drug interaction (DDI) and drug / alcohol interaction studies

53. Project Management

54. Clinical Data Management (Oracle Clinical)

55. Biostatistical & Pharmacokinetic Analysis

56. SAS Programming

57. Medical Writing

58. Regulatory submissionsClinical Study Reports PK Summaries IND, IDE, NDA (505b1 and b2), PMA, ANDA

62. Industry-leading staff with advanced degrees

64. Over 80 Methods Developed (GLP/non-GLP)

66. Development of stabilizing procedures for analyte with stability issues for sample collection

67. Fast turnaround for preclinical and clinical sample analysis for TK, PK and BE studies

68. Biomarker and immunogenicity method development/validations, PK, TK, PD sample analysisIntegrated Services Between our Phase I Clinic and Bioanalytical labs

70. MSD 6000

71. Spectramax

72. Abbott AxSYM System

73. Packard: Multiprobe II ex robotic liquid handling system

74. Tomtec: Quadra-3-SPE

75. Tecan: Genesis freedom 200

76. Watson LIMS Ver. 7.3

77. BIORAD CHEMI-Doc (quantitation of SDS-PAGE/WB)

78. GLP Labs

79. Assay Development / Transfer / Validation

80. Clinical / Pre-clinical Sample Testing

81. ADA – Anti Drug Antibody Assays (Immunogenicity)

82. PK/TK – Pharmacokinetics Assays

83. NAB – Neutralizing Antibody Assays

84. Cell Based Assays

87. Beijing, clinical services and regulatory affair, CMC center

89. Product development (formulation and pharmaceutical analysis)

92. 10 HPLC, GC, IR, UV-VIS, dissolution

93. 5 stability chambers

94. Tablet press/coater, capsule filler, etc.

100. Liquid: solution, suspension, emulsion for oral and parenteral administrationRELEASE PROFILE: IMMEDIATE, DELAYED, EXTENDED COATING: FILM, ENTERIC, CONTROLLED RELEASE cGMP CLINICAL TRIAL MATERIAL MANUFACTURING (SOLID AND STERILE DOSAGE FORMS)

102. Regulatory filings for new drug application

106. Thank You Roseann Affinito Business Development Manager – NJ Phone: (973) 934-1171